in-doe-METH-a-sin
Therapeutic Classification: antirheumatics, ductus arteriosus patency adjuncts (IV only), nonopioid analgesics
Pharmacologic Classification: nonsteroidal anti inflammatory drugs nsaids
BEERS REMS
Absorption: Well absorbed after oral administration in adults, incomplete oral absorption in neonates.
Distribution: Crosses the blood-brain barrier.
Protein Binding: 99%.
Half-Life: Neonates <2 wk: 20 hr; Neonates >2 wk: 11 hr; Adults: 2.6–11 hr.
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| PO (analgesic) | 30 min | 0.5–2 hr | 4–6 hr |
| PO-ER (analgesic) | 30 min | unknown | 4–6 hr |
| PO (anti-inflammatory) | up to 7 days | 1–2 wk | 4–6 hr |
| PO-ER (anti-inflammatory) | up to 7 days | 1–2 wk | 4–6 hr |
| IV (closure of PDA) | up to 48 hr | unknown | unknown |
Contraindicated in:
Use Cautiously in:
CV: edema, HF, hypertension, MI
Derm: rash
EENT: blurred vision, tinnitus
Endo:
IV
hypoglycemiaF and E: hyperkalemia,
IV
dilutional hyponatremiaGI: constipation, dyspepsia, nausea, vomiting, discomfort,
PO
GI BLEEDING, HEPATOTOXICITY, necrotizing enterocolitis, PANCREATITISGU: cystitis, hematuria, renal failure
Hemat: blood dyscrasias, prolonged bleeding time, thrombocytopenia
Local: phlebitis at IV site
Neuro: dizziness, drowsiness, headache, psychic disturbances, STROKE
Drug-drug:
Drug-Natural Products:
Anti-inflammatory
PDA Closure
Lab Test Considerations:
IV Administration:
NDC Code